We used the fruit fly Drosophila melanogaster as a cost-effective in vivo model to evaluate the efficacy of novel antibacterial peptides and peptoids for treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. A panel of peptides with known antibacterial activity in vitro and/or in vivo was tested in Drosophila. Although most peptides and peptoids that were effective in vitro failed to rescue lethal effects of S. aureus infections in vivo, we found that two lantibiotics, nisin and NAI-107, rescued adult flies from fatal infections. Furthermore, NAI-107 rescued mortality of infection with the MRSA strain USA300 with an efficacy equivalent to that of vancomycin, a widely applied antibiotic for the treatment of serious MRSA infections. These results establish Drosophila as a useful model for in vivo drug evaluation of antibacterial peptides.
Since the golden era of antibiotic drug development of the 1940s to 1960s, the development and spread of multidrug resistance (MDR) have become a huge burden to societies. At present, resistance to almost all known antibiotics has emerged with the sequential introduction of new or improved antibiotics in clinical and agricultural settings (1, 2). Therefore, continued development of new or improved antibiotics is of great importance to human health. However, new antibiotics are lacking, and few are under development for treatment of MDR infectious bacteria, as drug development is costly and success from in vitro discovery to application in clinical settings is limited.Bacterial infections with methicillin-resistant Staphylococcus aureus (MRSA) are no longer sporadic in their distribution and prevalence (3, 4). MRSA strains are associated with both community (CA-MRSA)-and hospital (HA-MRSA)-acquired infections, with the highly -lactam-resistant CA-MRSA clone USA300 accounting for up to 80% of all MRSA infections in the United States (5). High-level -lactam resistance is due to acquisition of staphylococcal cassette chromosome mec (SCCmec) elements, including the mecA gene, which encodes an alternative version of the penicillin binding protein (PBP2A) that is inducible (6, 7) and has a lowered affinity for -lactam antibiotics (8). SCCmec elements are often associated with carriage of genes encoding products involved in resistance to other antibiotics, including aminoglycoside-modifying enzymes, such as acetyltransferase, adenylyltransferase, or phosphotransferase (9). Due to this resistance, MRSA treatment often includes glycopeptide antibiotics, such as vancomycin, or oxazolidinones, such as linezolid. However, failure of vancomycin treatment has been reported for vancomycin-intermediate S. aureus (VISA) (10) and vancomycin-resistant S. aureus (VRSA) (11) strains. On the other hand, linezolid resistance is rare (12) but has been observed in association with mutations in the rRNA gene encoding the 23S RNA or through carriage of a Cfr rRNA methyltransferase gene (13,14). Furthermore, resistance to the last-resort antibiotic daptomycin has been reported (15,16...